目的 探讨阿托伐他汀钙对颈动脉粥样硬化患者血管内皮的保护作用。 方法 选取2010年10月－2011年8月颈动脉粥样硬化患者80例，随机分为治疗组和对照组。对照组给予阿司匹林肠溶片0.1 g，早饭后口服1次；治疗组在此基础上给予阿托伐他汀钙20 mg，每晚口服1次，10个月为1个疗程。分别在治疗前后进行颈动脉彩色多普勒超声检测颈动脉中膜厚度及颈动脉粥样硬化斑块面积，测定甘油三酯（TG）、总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）、一氧化氮（NO）、血管内皮素-1（ET-1）水平。两组患者在1个疗程治疗结束后停药12周，测定TG、TCH、LDL-C、HDL-C、NO、ET-1水平。 结果 与治疗前比较，治疗组患者的TG、TC、LDL-C、ET-1水平显著降低，HDL-C、NO水平显著升高（P＜0.01）。颈动脉中膜厚度和颈动脉粥样硬化斑块面积明显变小（P＜0.05）。对照组无明显变化。治疗组停药12周后与停药时比较，TG、TC、LDL-C、ET-1水平显著升高，HDL-C、NO水平明显降低（P ＜0.05）。对照组无明显变化。 结论 阿托伐他汀钙能显著改善颈动脉粥样硬化斑块患者的血管内皮功能、血脂水平，稳定颈动脉粥样硬化斑块，促进斑块逆转，且需要长期坚持服用。
Objective To explore the risk factors of carotid artery atherosclerotic plaque in ischemic stroke patients. Methods One hundred and forty-eight patients with ischemic stoke were allocated into two groups by ultrasonographic testing (80 with plaque and 68 without plaque). The carotid artery acoustic densitometry (IMT), blood pressure, blood glucose , blood lipid, fibriongen (FIB), c-reactive protein (CRP) were tested. First, single variable analysis was conducted and then multivariate non-condition stepwise logistic model analysis was conducted. Results Carotid IMT, age , total cholesterol (TC), low density lipoprotein (LDL)-CH, FIB, CRP level and the incidence of hypertension and diabetes were significantly higher in ischemic stroke patients with carotid artery plaques than patients without plaques (P≤0.05); Multiple logistic regression analysis showed the most important risk factors of plaques were CRP (OR=3.546, P=0.035) and FIB (OR=1.074, P=0.012) level. Conclusion The main risk factors of carotid atherosclerosis plaque are almost the same as atherosclerosis, such as age , hypertension ,diabetes, hyperlipidemia , high FIB and CRP level and increase in carotid IMT. CRP and FIB may play a crucial role in the development of carotid artery atherosclerosis plaque.